This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

With disgorgement hopes dead, US FTC drops remaining claim in pay-for-delay suit against AbbVie

By Max Fillion ( July 30, 2021, 22:01 GMT | Insight) -- With its hopes of seeking disgorgement from the pharmaceutical giant dead, the US Federal Trade Commission has dropped the last claim in its pay-for-delay suit accusing Abbvie of insulating testosterone replacement drug Androgel from generic competition. AbbVie is already subject to a commission order barring it from entering pay-for-delay agreements in which it pays a generic drugmaker to keep a competing drug off* the market, rendering duplicative any injunction a federal court could have imposed on AbbVie pursuant to the FTC claim dropped today. With its hopes of seeking disgorgement from the pharmaceutical giant dead, the US Federal Trade Commission has dropped the last claim in its pay-for-delay suit accusing Abbvie of insulating its testosterone replacement drug Androgel from generic competition....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections